MMP-7 as a prognostic marker in colorectal cancer

Tumour Biol. 2011 Apr;32(2):259-64. doi: 10.1007/s13277-010-0080-2. Epub 2010 Aug 28.

Abstract

Matrix metalloproteinase-7 is capable of degrading many extracellular matrix proteins and cellular adhesions. In many malignancies, it is overexpressed, and it plays a role in cancer progression by enhancing tumor invasion and thereby metastatic potential. The purpose of this study was to evaluate the association between MMP-7 tissue expression and prognosis in colorectal cancer. From 623 patients who underwent surgery for colorectal cancer, surgical specimens were collected into tissue array blocks and stained by immunohistochemistry for MMP-7. Specimens from 545 patients were suitable for analysis. In specimens from 105 patients (19.3%), MMP-7 scored as high; in 103 (18.9%), as moderate; and in 134 (24.9%), as mild. In 203 cases (37.2%), immunoreactivity was negative. A significant correlation appeared between MMP-7 immunoexpression and tumor differentiation. High MMP-7 positivity associated with poor prognosis during a 5-year follow-up. During longer follow-up, the differences in survival between groups disappeared. MMP-7 is a potential target for tumor therapy, which should be evaluated in clinical trials.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / diagnosis*
  • Adenocarcinoma / metabolism*
  • Adenocarcinoma / mortality
  • Adenocarcinoma, Mucinous / diagnosis
  • Adenocarcinoma, Mucinous / metabolism
  • Adenocarcinoma, Mucinous / mortality
  • Aged
  • Biomarkers, Tumor / metabolism*
  • Colorectal Neoplasms / diagnosis*
  • Colorectal Neoplasms / metabolism*
  • Colorectal Neoplasms / mortality
  • Disease Progression
  • Female
  • Follow-Up Studies
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Matrix Metalloproteinase 7 / metabolism*
  • Neoplasm Staging
  • Prognosis
  • Retrospective Studies

Substances

  • Biomarkers, Tumor
  • Matrix Metalloproteinase 7